The New Ropanasuri Journal of Surgery
Volume 4

Number 2

Article 3

12-31-2019

Association between Obesity and Hormone Receptor
Characteristics of Primary Breast Cancer at Cipto Mangunkusumo
General Hospital, Jakarta, in 2017
Hardian Gunardi
Training Program in Surgery, Faculty of Medicine Universitas Indonesia, hardian312@gmail.com

Diani Kartini
Division of Oncology Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, dr. Cipto
Mangunkusumo General Hospital, Jakarta, d.kartini@gmail.com

Follow this and additional works at: https://scholarhub.ui.ac.id/nrjs
Part of the Oncology Commons, and the Surgery Commons

Recommended Citation
Gunardi, Hardian and Kartini, Diani (2019) "Association between Obesity and Hormone Receptor
Characteristics of Primary Breast Cancer at Cipto Mangunkusumo General Hospital, Jakarta, in 2017," The
New Ropanasuri Journal of Surgery: Vol. 4 : No. 2 , Article 3.
DOI: 10.7454/nrjs.v4i2.1060
Available at: https://scholarhub.ui.ac.id/nrjs/vol4/iss2/3

This Article is brought to you for free and open access by the Faculty of Medicine at UI Scholars Hub. It has been
accepted for inclusion in The New Ropanasuri Journal of Surgery by an authorized editor of UI Scholars Hub.

New Ropanasuri Journal of Surgery 2019 Volume 4 No.2:9-14.

Association Between Obesity and Hormone Receptor Characteristics Of Primary Breast Cancer At
dr. Cipto Mangunkusumo General Hospital, Jakarta, In 2017
Hardian Gunardi,1 Diani Kartini.2
1. Training Program in Surgery, 2. Division of Oncology Surgery, Department of Surgery, Faculty of Medicine Universitas Indonesia, dr. Cipto Mangunkusumo
General Hospital, Jakarta
Email: hardian312@gmail.com Received: 17/Dec/2019 Accepted: 20/Dec/2019 Published: 31/Dec/2019
Website: https://scholarhub.ui.ac.id/nrjs/ DOI:10.7454/nrjs.v4i2.1060

Abstract
Introduction. Obesity is an independent risk factor and prognostic factor of primary breast cancer. Abundant adipose tissue would lead to
increment of blood estrogen level; thus, promoting proliferation of cancer cell, especially those with positive estrogen receptor (ER) and
progesterone receptor (PR). No study reported the association between obesity and hormone receptor characteristics of primary breast cancer in
Indonesia.
Method. We collected cases of primary breast cancer which is diagnosed and undergone immunohistochemistry examination at Cipto
Mangunkusumo General Hospital in 2017. The subjects divided into obese group and non-obese group. The ER and PR characteristics of both
groups were compared
Results. We collected 202 cases of primary breast cancer, with 89 cases (44%) in obese group and 113 cases (56%) in non-obese group. The mean
body mass index (BMI) of the subjects was 24.45±4.3. Both groups were similar in terms of age, menopausal status, stage, histopathological
morphology and grade. No significant association was found between obesity and ER or PR. We analyzed correlation between BMI and the
percentage of expressed hormone receptor, but no correlation was found. This finding did not conform with other Western studies. Difference in
characteristics of the subjects and other hormonal factors might contribute to the outcome.
Conclusion. There is no association between obesity and hormone receptor characteristics of primary breast cancer at Cipto Mangunkusumo
General Hospital in 2017.
Keywords: obesity, hormone receptor, estrogen, progesterone, primary breast cancer

Introduction
Breast cancer is the most common cancer in females in the
world. It has the highest rate of mortality due to cancer in
Indonesia, accounted for 22% of all cancer mortality. 1 The
estimated prevalence of breast cancer in Indonesia was 36,2 in
every 100.000 persons, with mortality around 18.6 cases in
every 100.000.2 Compared to developed countries, the
mortality rate in Indonesia was higher due to more advanced
stage at the time of diagnosis.2,3
Breast cancer and obesity are two related conditions. Obesity
referred to an independent risk factor for breast cancer. 4
Gaining 5 kg/m2 of body mass index (BMI) increases the risk
by 2%.5 Evidence showed that 50% of patients with breast
cancer were overweight or obese at the diagnosis insitututed. 6
Majority of patients have a weight gain during and after
completion of therapy. Changes in the body metabolism,
physical activity, dietary habits, and changes in menstrual
status contribute to weight gain in breast cancer.7 Thus, the
increment of weight after diagnosis become a predictor for
higher mortality and worsen the prognosis. 8 Studies showed
that there was significant weight gains in younger age,
postmenopausal breast cancer, positive hormone receptor
breast cancer, advance stage, pre-diagnostic underweight, and
smokers.8 Obesity has also become an independent prognostic
factor for mortality and metastatic disease in breast cancer. 9
Obese patients have correlation to a higher stage when the

diagnosis instituted, with larger tumor size, higher lymph node
ratio, more and aggressive tumors.10,11 Obese females also
related with higher rates of recurrent disease, second primary
cancer, more inferior quality of life, higher risk of lymphedema
and other comorbidities in breast cancer, e.g., diabetes,
hypertension, and another cardiovascular disease.6
The difference in cancer subtype became a contributing factor
to prognosis in the obese patient. Obesity is associated with a
higher risk of positive hormone receptor (estrogen or
progesterone receptor) breast cancer.11-14 An increase in
circulating estrogen levels and its bioavailability might play a
role. Increase adiposity reflecting obesity leads to an increase
in aromatase in adipose tissue. Thus, increasing circulating
estrogen levels.15 Sex hormone-binding globulin (SHBG), a
glycoprotein produced by the liver that restricts estrogen
biological activity, will decrease in obese; thus reduction on its
level would lead to a higher risk of positive hormone receptor
breast cancer.15-18 Obesity would also increase insulin-like
growth factor (IGF-1): a local factor promoting breast cell
proliferation and differentiation, enhancing tumor growth. 19
Increase in leptin and adiponectin in an obese patient would
also initiate proinflammatory cascade, leading to tumor
progression.20,21
To date, there is no single study that reported the association
between obesity and hormone receptor characteristics of breast
cancer in Indonesia. Most of the evidence is based on Western
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reviews, while ethnicity might play a role in subtypes of breast
cancer.22 Thus we conducted a study aimed to find out the
association between obesity and hormone receptor
characteristics of primary breast cancer in our center, which is
Indonesian specific characteristics.
Method
This was a cross-sectional analytic study that compared the We
conducted a cross-sectional study using secondary data from
the medical reports. Data on those diagnosed with primary
breast cancer and managed at dr. Cipto Mangunkusumo
General Hospital during 2017. Those included in the study
were: adult females, diagnosis of breast cancer confirmed with
the histopathological examination, and immunohistochemistry
for hormone receptor status. Breast metastasis with another
origin, and recurrent diseases excluded. Age, body weight,
height, menstrual status, tumor stage, histopathological
morphology, the grading of tumor, ER status, and PR status and
BMI calculated with body weight (kg) / height (m) 2 were

variables of the study. The subjects classified into two
categories based on the Asian classification of obesity: obese
group if the BMI >25 and non-obese group if the BMI ≤25.23
The characteristics of both groups were compared. The
association between obesity and hormone receptor
characteristic of primary breast cancer subjected to analysis.
The proportion of positive hormone receptors of each group
and the correlation between BMI and hormone receptor
expression analyzed.
The study approved by independent reviewer board of Faculty
of Medicine, Universitas Indonesia. 341/UN2.F1/ETIK/2018.
Results
Those were 202 subjects diagnosed with breast cancer during
2017 and met the criteria. The mean BMI of the subjects was
24.45 ± 4.3. The characteristics of the subjects presented in
table 1. Obese group comprise of 89 subjects (44%), and nonobese group of 113 subjects (56%).

Table 1. Comparison between hormone receptor characteristic in obese group and non-obese
Age
Menopausal Status
−
Pre-menopause
−
Post-menopause
Stage (TNM)
T
−
Tis
−
T0
−
T1
−
T2
−
T3
−
T4
N
−
N0
−
N1
−
N2
−
N3
M
−
M0
−
M1
Category
−
Early breast cancer
−
Locally advanced breast cancer
−
Metastatic breast cancer
Histopathological morphology
−
Ductal invasive
−
Lobular invasive
−
DCIS
−
Others
Grade
−
I
−
II
−
III

Overall
49.94 (SD ±
10.92)

Obese group
51.12 (SD ±
11.26)

Non-Obese group
49 (SD ± 10.61)

P value
p = 0.171

129 (63.9%)
73 (36.1%)

55 (61.8%)
34 (38.2%)

74 (65.5%)
39 (34.5%)

p = 0.588

4 (2%)
1 (0.5%)
4 (2.0%)
64 (31.7%)
67 (33.2%)
62 (30.7%)

2 (2.2%)
0 (0)
0 (0)
30 (33.7%)
30 (33.7%)
27 (30.3%)

2 (1.8%)
1 (0.9%)
4 (3.5%)
34 (30.1%)
37 (32.7%)
35 (31%)

81 (40.1%)
78 (38.6%)
32 (15.8%)
11 (5.4%)

33 (37.1%)
39 (43.8%)
13 (14.6%)
4 (4.5%)

48 (42.5%)
39 (34.5%)
19 (16.8%)
7 (6.2%)

166 (82.2%)
36 (17.8%)

73 (82%)
16 (18%)

93 (82.3%)
20 (17.7%)

41 (20.3%)
126 (62.4%)

17 (19.1%)
57 (64%)

24 (21.2%)
69 (61.1%)

35 (17.3%)

15 (16.9%)

20 (17.7%)

162 (80.2%)
19 (9.4%)
4 (2%)
17 (8.4%)

71 (79.8%)
9 (10.1%)
2 (2.1%)
7 (8%)

91 (80.5%)
10 (8.8%)
2 (1.8%)
10 (8.9%)

41 (20.3%)
104 (51.5%)
57 (28.2%)

21 (23.6%)
49 (55.1%)
19 (21.3%)

20 (17.7%)
55 (48.7%)
38 (33.6%)

The age, menopausal status, cancer stage, histopathological
morphology, and grade of the tumor were similar between the
two groups. The association between obesity and hormone
receptor (ER and PR) characteristic analyzed with the ChiSquare test, presented in Tables 2 and 3, we found no
significant association this study. Further analysis proceeded to
find out the correlation between BMI and expression of the
hormone receptor. Pearson correlation test showed no
significant correlation between BMI and neither estrogen

p = 0.903

p = 0.142

receptor expression (p = 0.588) nor progesterone receptor
expression (p = 0.236).
Table 2 Association between obesity and ER characteristic of primary
breast cancer
Obese group
Non-obese group

ER (+)
56 (62.9%)
72 (63.7%)
128

ER (-)
33 (37.1%)
41 (36.3%)
74

89
113
p = 0.907*)

*) Chi–Square
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Table 3 Association between obesity and PR characteristic of primary
breast cancer
Obese group
Non-obese group

PR (+)
49 (55.1%)
59 (52.2%)
108

PR (-)
49 (44.9%)
54 (47.8%)
94

no significant association displayed in premenopausal subjects nor
postmenopausal subjects

Discussion
89
113
p = 0.776*)

*) Chi–Square

Figure 1. Correlation between BMI and ER expression (%ER) in
primary breast cancer
Table 4 Statistical analysis between obesity and ER characteristic in
pre-menopause primary breast cancer
ER (+)

ER (-)

Obese group

34 (61.8%)

21 (38.2%)

55

Non-obese group

45 (60.8%)

29 (39.2%)

74

79

50

p = 0.908*)

*) Chi Square

Table 5Statistical analysis between obesity and PR characteristic in
pre-menopause primary breast cancer
PR (+)

PR (-)

Obese group

31 (56.4%)

24 (43.6%)

55

Non-obese group

36 (48.6%)

38 (51.4%)

74

67

62

p = 0.386*)

*) Chi Square

Table 6. Statistical analysis between obesity and ER characteristic in
post-menopause primary breast cancer
ER (+)

ER (-)

Obese group

22 (64.7%)

12 (35.3%)

34

Non-obese group

27 (69.2%)

12 (30.8%)

39

49

24

p = 0.681*)

*) Chi Square
-

Table 7 Statistical analysis between obesity and ER characteristic in
pre-menopause primary breast cancer
PR (+)

PR (-)

Obese group

18 (52.9%)

16 (47.1%)

34

Non-obese group

23 (59%)

16 (41%)

39

41

32

p = 0.604*)

*) Chi Square

Subgroup analysis performed to evaluate the association between the
obese group and the non-obese group based on menopausal status —

The increasing prevalence of obesity become a significant
problem in developed and developing countries, and it is related
to the increasing incidence of breast cancer.24 A thorough
understanding of the relationship between obesity and breast
cancer become essential to determine comprehensive
management and its prognosis, especially in the obese
population.10 The relationship between breast cancer and
obesity was explained initially by Abe et al. in 1976, showed
that a 20% increment of ideal body weight would lead to bigger
tumor size, higher lymphatic invasion, and more reduced
survival in females with breast cancer.25 Obesity is known as
an independent risk factor for breast cancer, especially in the
postmenopausal period. Obesity would increase the risk of
breast cancer by 12-15% post-menopause, while obesity and
the risk for breast cancer in pre-menopause females is still
controversial.4,26
Studies showed a strong correlation between obesity and breast
cancer with positive hormone receptor (ER+/PR+), but not in
other subtypes.4 Our study shows the different results: there is
no significant association between obesity and hormone
receptor characteristics in primary breast cancer. The difference
in population characteristics and other factors influencing
hormone receptor expression in primary breast cancer could
affect this outcome.
Our population characteristic is different from the population
characteristic in Western studies. During the period from 2011
until 2014, the prevalence of obesity in premenopausal females
aged 20 to 59 was 35% in the United States (US).27 The number
is much lower in the Asia region. In Singapore, the study
showed that 35% of female aged 18-19 was overweight, and
14% classified as obese.28 Data from Selangor, Malaysia,
showed that the prevalence of obesity in Malaysian females
aged 20-59 was 16,7%.29 In Indonesia, the prevalence of
overweight in adult females aged 20-75 was 26,4%, and the
prevalence of obesity was 13.22% in 2007.30 Difference in
socioeconomic status, culture, and ethnicity could underlie this
difference in the prevalence of obesity.28
There are also differences in age and stage of breast cancer
during the time of diagnosis in our study and Western studies.
The mean age of diagnosis in our study was 49.94 years
(SD±10.92), while in the US, only 20% of breast cancer
diagnosed under the age of 50.27. In 2010 until 2014, the median
age of breast cancer diagnosis in the US was 62 years. 31 The
stage of initial diagnosis also differs. Our study reveals that
most cases diagnosed in locally advanced stage (62,4%),
followed by an early stage (20,3%) and metastatic stage
(17.3%). In the US, 63% of the cases diagnosed in early stage,
28% in the locally advanced stage, and 6% in metastatic stage.32
Estrogen and progesterone are the essential hormones in the
etiology of breast cancer due to their proliferative effect.33 The
proliferative effect of these hormones mediated with each
receptor and the receptor expression of each hormone in breast
tissue reflect their responses to specific hormones. The estrogen
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receptor is a nuclear receptor acting as a ligand-dependent
transcription factor that regulates the gene that plays a role in
proliferation, invasion, angiogenesis, and survival of breast
cancer cells. This receptor will, directly and indirectly, increase
tyrosine kinase of many growth factor receptors (e.g., HER1,
HER2, and insulin-like growth factor-1 receptor) and signaling
molecule such as membrane protein, signaling adaptor
molecule, and cellular kinase.34
Progesterone receptor expression considered as a part of
pathway mediated by estrogen; thus, PR expression considered
to picture ER expression.35,36 Around 96% cell expressing one
of the receptor hormone (either ER or PR) will express the
other.36 PR expression does not reflect the response to
hormonal therapy, but if combined with ER, they will give
more prognostic value.37
Breast cancer with positive hormone receptors has different
behavior. It shows the stronger clinical response to hormonal
therapy, better differentiation in morphologic appearance,
increasing incidence with age, and slowing down with
menopause.12 Risk factors for different subtypes of breast
cancer were studied, but the result showed some controversies.
The study of Oh (2017) showed in healthy breast tissue,
advance age-related to higher ER expression, although it
showed no relation with PR expression. Body height and BMI
influenced PR expression but did not affect ER expression. The
duration of breastfeeding affected ER expression, but other
reproductive factors such as age of menarche, parity, age of first
childbirth, number of childbirth, menopausal status, and age of
menopause did not affect ER or PR expression in healthy breast
tissue.38 Alcohol consumption related to ER expression, but
family history of breast cancer did not associate with hormone
receptor expression.38

In pre-menopause females, the relation between obesity and
breast cancer is still controversial. Van de Brandt et al. stated
that premenopausal obesity would lower the risk of breast
cancer.4 Kawai et al. showed that increasing BMI after age 18
would increase the risk of triple-negative breast cancer while
decreasing the risk of positive hormone receptor breast
cancer.42 One of the hypotheses supporting this theory was the
high level of estrogen synthesis from ovaries, and peripheral
tissue would elicit a negative feedback mechanism in
hypothalamus-pituitary axis, suppressing ovarian activity and
decrease progesterone level as a promoter of breast
proliferation.38
Ethnicity may play a role in hormone receptor expression in
primary breast cancer. Munsul (2013) added racial factor as a
contributing factor since the risk of breast cancer increase in
obese Caucasian and Negroid females, but not in Hispanics.13
A further question arises about the role of race in the
association between obesity and positive hormone receptor
breast cancer. There is no study about this in Asia yet. Thus,
the role of the race could not be concluded.
This study has a limitation. The timing of measurement of BMI
was not equal, whether the BMI was measured at the time of
diagnosis, or while receiving and even completing any
treatment. Changes in body weight during treatment are not
taking into account. This study used secondary data from the
medical report, so information bias and selection bias should be
taken into account. No other factors related to increased
estrogen exposure such as parity, delayed in childbearing, age
of menarche and exogenous hormonal use analyzed in this
study. Incomplete medical record data became our major
limitation.
Conclusion

Factors affecting ER and PR expression in breast cancer tissue
seem to differ. Althuis stated that factors related to breast
cancer with positive hormone receptors are factors related to
hormonal exposure, such as nulliparity, delayed in
childbearing, age of menarche, and the use of exogenous
hormonal therapy. Our study did not include these factors.

In this study, there is no significant association between obesity
and hormone receptor characteristic of primary breast cancer in
dr. Cipto Mangunkusumo General Hospital in 2017 in both
premenopausal and postmenopausal periods.

Menopausal status is an essential factor in the association of
obesity and breast cancer. Adipose tissue would produce
aromatase, an enzyme responsible for estrogen biosynthesis,
which has more role in post-menopause.39 Subgroup analysis
performed to evaluate the association between obesity and
receptor hormone characteristics in pre-menopause and postmenopause period, but no significant association found.

The author(s) declare have no conflict of interest to disclose

The study by Women's Health Initiative in 2015 showed that in
postmenopausal females aged 50 to 79, obesity (especially with
BMI more than 35 kg/m2) had a higher risk of developing breast
cancer.39 Other studies showed a similar result.4,6,40 This finding
seems to be found only in positive hormone receptor breast
cancer. In contrast, negative hormone receptor and triplenegative disease did not have any correlation with BMI. 38,39
Postmenopausal obesity-related to less aggressive tumor
subtype, i.e. Positive ER and PR, negative HER2, low Ki67,
positive Bcl-2, and negative p53, especially in patients did not
receive hormonal therapy.40

Disclosure

References
1. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and
mortality of female breast cancer in the Asia-Pacific region.
Cancer Biol Med. 2014;11:101-15.
2. Ng CH, Pathy NB, Taib NA, Teh YC, Mun KS, Amiruddin A, et
al. Comparison of breast cancer in Indonesia and Malaysia – a
clinicopathological study between Dharmais Cancer Centre
Jakarta and University Malaya Medical Centre, Kuala Lumpur.
Asia Pac J Can Prev. 2011;12:2943-6.
3. Suzanna E, Siraqit T, Rahayu PS, Shalmont G, Anwar E,
Andalusia R, et al. Registrasi kanker berbasis rumah sakit di RS
Kanker Dharmais-Pusat Kanker Nasional, 1993-2007. Indonesian
Journal of Cancer. 2012;6:1-12.
4. Ligibel JA, Strickler HD. Obesity and its impact on breast cancer:
tumor incidence, recurrence, survival, and possible interventions.
ASCO educational book 2013.

12

5. Liu K, Zhang W, Dai Z, Wang M, Tian T, Liu X, et al. Association
between body mass index and breast cancer risk: evidence based
on a dose-response meta-analysis. Cancer Manag Res
2018;10:143-51.
6. DSM Chan, T Norat. Obesity and breast cancer: not only a risk
factor of the disease. Curr Treat Options in Oncol. 2015;16:22-39.
7. Champ CE, Volek JS, Siglin J, Jin L, Simone NL. Weight gain,
metabolic syndrome, and breast cancer recurrence: are dietary
recommendations supported by the data? Int J Breast Ca 2012;
2012:1-9. Article ID 506868.
8. Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M,
Irwin ML. Weight gain after breast cancer diagnosis and all-cause
mortality: systematic review and meta-analysis. JNCI J Natl
Cancer Inst 2015;107(12):1-15. DOI: 10.1093/jnci/djv275.
9. M Ewertz, MB Jensen, KA Gunnarsdottir, I Hejris, EH Jakobsen,
D Nielson. Effect of obesity on prognosis after early-stage breast
cancer. J Clin Oncol. 2011;29(1):25-31.
10. Lee K, Kruper L, Dieli-Conwright CM, Mortimer JE. The impact
of obesity on breast cancer diagnosis and treatment. Curr Oncol
Rep 2019;21(41):1-6.
11. Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis:
evidence, challenges, and opportunities. J Clin Oncol
2016;34(35):4203-16.
12. MD Althuis, JH Fergenbaum, M Gracia-Closas, LA Brinton, MP
Madigan, ME Sherman. Etiology of hormone receptor defined
breast cancer: a systematic review of the literature. Cancer
Epidemiol Biomarkers Prev. 2004;13(10):1558-68.
13. MF Munsell, BL Sprague, DA Berry, G Chisholm, A TrenthamDietz. Body mass index and breast cancer risk according to
postmenopausal estrogen-progestin use and hormone receptor
status. Epidemiol Rev. 2014;36:114-36.
14. A Vrieling, K Buck, R Kaaks, J Chang-Claude. Adult weight gain
in relation to breast cancer risk by estrogen and progesterone
receptor status: a meta-analysis. Breast Cancer Res Treat.
2010;123(3):641-9.
15. MP Cleary, ME Grossman. Obesity and breast cancer: the estrogen
connection. Endocrinology. 2009;150(6):2537-42.
16. N Fortunati, MG Catalano, G Boccuzzi, R Frairia. Sex HormoneBinding Globulin (SHBG), estradiol and breast cancer. Molecular
and Cellular Endocrinology. 2010;316:86-92.
17. W Rosner, DJ Hryb, SM Kahn, AM Nakhla, NA Romas.
Interactions of sex hormone-binding globulin with target cells.
Mol Cell Endocrinol. 2010;316:79-85.
18. XY He, YD Liao, S Yu, Y Zhang, R Wang. Sex Hormone Binding
Globulin and Risk of Breast Cancer in Postmenopausal Women:
A Meta-Analysis of Prospective Studies. Horm Metab Res.
2015;47:485-90.
19. Coughlin SS, Smith SA. The insulin-like growth factor axis,
adipokines, physical activity, and obesity in relation to breast
cancer incidence and recurrence. Cancer Clin Oncol 2015;4(2):2431.
20. Li YR, Ro V, Tchou JC. Obesity, metabolic syndrome, and breast
cancer: from prevention to intervention. Curr Surg Rep
2018;6(3):7.
21. Ando S, Gelsomino L, Panza S, Giordano C, Bonofigilio D,
Barone I. Obesity, leptin and breast cancer: epidemiological
evidence and proposed mechanisms. Cancers (Basel)
2019;11(1):62.
22. Curtis E, C Quale, D Haggstrom, R Smith-Bindman. Racial and
ethnic differences in breast cancer survival: how much is
explained by screening, tumor severity, biology, treatment,
comorbidities, and demographics. Cancer 2008;112(1):171-80.

23. Pan WH, Yeh WT. How to define obesity? Evidence-based
multiple action points for public awareness, screening, and
treatment: an extension of Asian-Pacific recommendations. Asia
Pac J Clin Nutr. 2008;17(3):370–374.
24. Deurenberg-Yap M, Schmidt G, van Staveren WA, P Deurenberg.
The paradox of low body mass index and high body fat percentage
among Chinese, Malays, and Indians in Singapore. Int J Obes
Relat Metab Disord. 2000;24:1011-7.
25. Abe R, Kumagai N, Kimura M, Hirosaki A, Nakamura T.
Biological characteristics of breast cancer in obesity. Tohoku J
Exp Med. 1976; 120(4):351-9.
26. White AJ, Nichols HB, Bradshaw PT, Sandler DP. Overall and
central adiposity and breast cancer risk in the sister study. Cancer
2015; 121(20):3700-8.
27. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER,
Slingerland JM. Obesity and adverse breast cancer risk and
outcome: mechanistic insights and strategies for intervention. Ca
Cancer J Clin 2017;67:378-97.
28. Ramachandran A, Snehalatha C. Rising burden of obesity in Asia.
J Obes 2010;2010:868573.
29. Sidik SM, Rampal L. The prevalence and factors associated with
obesity among adult women in Selangor, Malaysia. Asia Pac Fam
Med 2009;8(1):2.
30. Roemling C, Qaim M. Obesity trends and determinants in
Indonesia. Appetite 2012;58(3):1005-13.
31. Howlander N, Noone AM, Krapcho M, Miller D, Bishop K,
Kosary CL, et al. SEER Cancer Statistics Review, 1975 - 2014,
National
Cancer
Institute.
Bethesda,
MD,
https://seer.cancer.gov/archive/csr/1975_2014/,
based
on
November 2016 SEER data submission, posted to the SEER
website, April 2017.
32. Institute of Medicine (US) and National Research Council (US)
National Cancer Policy Board; Hewitt M, Herdman R, Holland J,
editors. Meeting Psychosocial Needs of Women with Breast
Cancer. Washington (DC): National Academies Press (US); 2004.
2, Epidemiology of Breast Cancer. Available on website
https://www.ncbi.nlm.nih.gov/books/NBK215952/.
33. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones
and Breast Cancer Collaborative Group. Endogenous sex
hormones and breast cancer in postmenopausal women: reanalysis
of nine prospective studies. J. Natl Cancer Inst. 2002;94:606–616.
34. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor
status in breast cancer: re-shaping the paradigm. Clin Cancer Res
2007;13(2):6921-5.
35. Lee M, Lee CS, Tan PH. Hormone receptor expression in breast
cancer: post-analytical issues. J Clin Pathol 2013;66(6):478-84.
36. Clarke RB. Steroid receptors and proliferation in the human breast.
Steroids 2003;68(10-13):789-94.
37. Lim E, Palmieri C, Tilley WD. Renewed interest in the
progesterone receptor in breast cancer. Br J Cancer
2016;115(8):909-11.
38. Oh H, Eliassen AH, Beck AH, Rosner B, Schnitt SJ, Collins LC,
et al. Breast cancer risk factors in relation to the estrogen receptor,
progesterone receptor, insulin-like growth factor-1 receptor, and
Ki67 expression in normal breast tissue. NPJ Breast Cancer
2017;3:39.
39. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE,
Chlebowski R, Carty CL, et al. Overweight, obesity, and
postmenopausal invasive breast cancer risk: A secondary analysis
of the women's health initiative randomized clinical trials. JAMA
Oncol. 2015, 1, 611–621.

13

40. R Weir, P Day, W Ali. Risk factors for breast cancer in women: a
systematic review of the literature. NZHTA Report2007. p. 1-361.
41. Nattenmuller, C.J.; Kriegsmann, M.; Sookthai, D.; Fortner, R.T.;
Steffen, A.; Walter, B.; Johnson T, Kneisel J, Katzke V, Bergmann
M, et al. Obesity as risk factor for subtypes of breast cancer:
Results from a prospective cohort study. BMC Cancer 2018, 18,
616.

14

